News Center

Home page

Peak Report

News reports

Announcement of Jianfeng Group Lin2017 -005 on Subsidiary Obtaining Drug Clinical Trial Approval

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviations: Jianfeng Group Number: Pro 2017-005

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Subsidiaries Obtaining Approval for Drug Clinical Trials

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

1. Summary

Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, received the "Drug Clinical Trial Approval Document" (Deoxypodophyllotoxin for Injection, Approval Document No.: 2017L01082 ) and (Deoxypodophyllotoxin, Approval Document No: 2017L01083)(hereinafter collectively referred to as "DPT"). The relevant details are hereby announced as follows:

2. drug basic information content

(I) deoxypodophyllotoxin

drug name: deoxypodophyllotoxin

English name: Deoxypodophyllotoxin

dosage form: bulk drug

application items: domestic Drug Registration

Registration Classification: Chemical Drug Class 1

Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University

Approval Conclusion: "According to the the People's Republic of China Drug Administration Law and relevant regulations, after examination, this product meets the relevant requirements of drug registration and agrees to conduct clinical trials of this product preparation."

(II) deoxypodophyllotoxin for injection

drug name: deoxypodophyllotoxin for injection

English name: Deoxypodophyllotoxin for Injection

dosage form: injection

application items: domestic drug registration

specification: 100mg

registration classification: chemical drugs category 1

applicant: Zhejiang Jianfeng pharmaceutical co., ltd. and China pharmaceutical university

approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, this product meets the relevant requirements of drug registration and agrees to carry out clinical trials."

Research and Development and Registration of 3. Drugs

DPT Project was established in March 104 by 2012. Jianfeng Pharmaceutical Co., Ltd. is a new anti-tumor drug developed in cooperation with China Pharmaceutical University. The registration classification belongs to Class 1 of chemical drugs. The first DPT clinical trial application submitted by Jianfeng Pharmaceutical was accepted on July 27, 2016 (acceptance numbers: CXHL1600201 Zhejiang, CXHL1600202 Zhejiang). DPT is an alkaloid antineoplastic drug with tentative indications for lung cancer, breast cancer and gastric cancer, which will be finalized based on clinical trial results. As of the date of this announcement, the accumulated research and development investment and other related expenditures of the DPT project of Jianfeng Pharmaceutical Co., Ltd. totaled about 34.12 million yuan.

Market Situation of Similar Drugs in 4.

Currently, the same alkaloid anti-tumor drugs listed in China mainly include paclitaxel, vinorelbine and docetaxel. The main manufacturers of paclitaxel injection include Yangzijiang Pharmaceutical Group Co., Ltd., Beijing Shuanglu Pharmaceutical Co., Ltd., Haizheng Pfizer Pharmaceutical Co., Ltd., etc, the main manufacturers of Vinorelbine include Jiangsu Haosen Pharmaceutical Group Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Haizheng Pfizer Pharmaceutical Co., Ltd., etc., and the main manufacturers of docetaxel injection include Jiangsu Hengrui Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd.

According to IMS database statistics, the global sales of the above three drugs in 2015 were 16.46, 1.07 and 0.669 billion US dollars respectively, totaling 2.422 billion US dollars.

5. products still need to go on the market.

DPT is currently in the approved clinical trial stage. Jianfeng Pharmaceutical will complete the clinical trial according to the requirements of the "Drug Clinical Trial Approval". After the clinical trial is completed, it will declare for production. It can only produce and market after passing the review and approval of CFDA and obtaining the drug production approval.

Impact of 6. on Listed Companies and Risk Tips

The company has obtained the "Drug Clinical Trial Approval" this time, which will not have a significant impact on the company's recent operating results.

Due to the particularity of drug research and development, there are unpredictable risks such as long cycle and many links from clinical trials to commissioning. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.

hereby announce

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

March 22, 2017

More information

Go, go, go! Don't panic!

On the afternoon of June 9, Peak Cable Company organized all employees to learn fire fighting knowledge and conducted fire fighting and emergency escape drills. Since June, the subordinate enterprises of the company have organized training, learning and drills related to production safety according to their own characteristics and combined with the actual work. Safety production month series of activities carried out in an orderly manner.

2022

06-13

Spike Postdoctoral Research Papers on International Frontier Journals

Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease" were published in the internationally renowned academic journal "Frontiers in Pharmacology. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.

2022

06-01

Daye Peak QC Achievements Won the Third Prize of Huangshi City

On May 7, Huangshi City Quality Strong City Working Committee organized a 2022 QC Results Conference. The QC project of "Technical Transformation of Ore Limestone Batching System" of Daye Peak Cement Company won the third prize.

2022

06-01

Peak International Trade was awarded the "Excellent Designated Delivery Warehouse" by the Big Business Institute"

On April 28, Dalian Commodity Exchange held an online working meeting to announce the results of the 2021 excellent delivery warehouse and delivery warehouse excellent futures personnel selection, peak international trading company won the 2021 "excellent designated delivery warehouse" title, futures commissioner Ruan Weihang won the "excellent futures personnel" title.

2022

06-01

Cranberry extract combination identification detection method won the invention patent

After cranberry extract products were included in the "Zhejiang Province Key High-tech Product Development Project Plan" in 2021, Jianfeng Health Technology Company recently obtained an invention patent for the identification and detection method of cranberry extract. This new combined identification and detection method developed by Jianfeng Health identifies whether catechin or procyanidin B2 is added in cranberry extract by thin layer analysis, and then detects the unique A- type procyanidin and its chromatographic distribution in cranberry extract by high performance liquid chromatography, so as to improve the accuracy of product judgment. The identification method has the characteristics of accurate results and short detection time, which is of great significance to standardize the cranberry extract market and promote the healthy development of the industry, and has been unanimously recognized by peers.

2022

05-20

Daye Peak Manufacturing Department Won the Title of "Worker Pioneer" in Hubei Province

A few days ago, the manufacturing department of Daye Peak Cement Company was awarded the title of "Worker Pioneer" by the Hubei Provincial Federation of Trade Unions. Daye Jianfeng Manufacturing Department not only continued to actively explore and achieved good results in energy saving and consumption reduction, technological transformation, product quality process control, and economic responsibility system to guide management, but also improved Daye Jianfeng's overall operation level and won Huangshi City The seventh "Mayor Quality Award" created conditions and was fully affirmed by government departments at all levels.

2022

05-20

< 1...5 6 7...61 > 跳转到页